Register Login

Antiplatelet Therapy

Primary CVD Disease: Is Low Dose ASA Effective?

Thanks to Dean Willett, Precision BioLogic Inc, for pointing me to this October 12, 2021 US Preventive Services Task Force release, “Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication,” which recommends against daily low-dose aspirin as a means to reduce the risk of cardiovascular disease, ischemic stroke, and colorectal cancer regardless of age or comorbities. […]
read more

Zontivity (vorapaxar)

I’m curious about how many of our participants monitor vorapaxar (Zontivity®, New American Therapeutics, Inc) antiplatelet therapy. Vorapaxar is the only protease-activated receptor-1 (PAR-1) antagonist that reduces thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral arterial disease, FDA-approved in 2014. Vorapaxar is used alongside dual antiplatelet therapy (aspirin and clopidogrel; aspirin and ticagrelor) […]
read more

Ticagrelor Antibacterial Property

Click below to see a May 9, 2019 article that links ticagrelor (Brilinta) antiplatelet therapy with its putative anti-gram-positive bacterial property, including Methacillin-resistant Staph aureus and Vancomycin-resistant enterococcus. It appears that platelets are able to sequester the drug in sites of infection. Lancellotti P, Musumeci L, Jacques N, et al. Antibacterial activity of ticagrelor in […]
read more